BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

<p>– BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia –  The U.S. Food and Drug Administration (FDA) and European Union (EU) European Medicines Agency (EMA) shared positive feedback that the PROPEL 3 trial design […]</p>
<p>The post <a href="https://forextv.com/top-news/bridgebio-announces-first-child-dosed-in-propel-3-its-phase-3-clinical-trial-for-infigratinib-in-children-with-achondroplasia/">BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>